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ABSTRACT
The first part of this work investigates the molecular epidemiology of a human 
enterovirus (HEV), echovirus 30 (E-30).  This project is part of a series of studies 
performed in our research team analyzing the molecular epidemiology of HEV-B 
viruses. A total of 129 virus strains had been isolated in different parts of Europe. 
The sequence analysis was performed in three different genomic regions: 420 
nucleotides (nt) in the VP4/VP2 capsid protein coding region, the entire VP1 capsid 
protein coding gene of 876 nt, and 150 nt in the VP1/2A junction region. The 
analysis revealed a succession of dominant sublineages within a major genotype. 
The temporally earlier genotypes had been replaced by a genetically homogenous 
lineage that has been circulating in Europe since the late 1970s. The same genotype 
was found by other research groups in North America and Australia. Globally, other 
cocirculating genetic lineages also exist. The prevalence of a dominant genotype 
makes E-30 different from other previously studied HEVs, such as polioviruses and 
coxsackieviruses B4 and B5, for which several coexisting genetic lineages have 
been reported. 
The second part of this work deals with molecular epidemiology of human 
rhinoviruses (HRVs). A total of 61 field isolates were studied in the 420-nt stretch in 
the capsid coding region of VP4/VP2. The isolates were collected from children 
under two years of age in Tampere, Finland. Sequences from the clinical isolates 
clustered in the two previously known phylogenetic clades. Seasonal clustering was 
found. Also, several distinct serotype-like clusters were found to co-circulate during 
the same epidemic season. Reappearance of a cluster after disappearing for a season 
was observed. The molecular epidemiology of the analyzed strains turned out to be 
complex, and we decided to continue our studies of HRV. 
Only five previously published complete genome sequences of HRV prototype 
strains were available for analysis. Therefore, all designated HRV prototype strains 
(n=102) were sequenced in the VP4/VP2 region, and the possibility of genetic 
typing of HRV was evaluated. Seventy-six of the 102 prototype strains clustered in 
HRV genetic group A (HRV-A) and 25 in group B (HRV-B).  Serotype 87 clustered 
separately from other HRVs with HEV species D. The field strains of HRV 
represented as many as 19 different genotypes, as judged with an approximate 
demarcation of a 20% nt difference in the VP4/VP2 region.  
The interserotypic differences of HRV were generally similar to those reported 
between different HEV serotypes (i.e. about 20%), but smaller differences, less than 
10%, were also observed.  Because some HRV serotypes are genetically so closely 
related, we suggest that the genetic typing be performed using the criterion “the 
closest prototype strain”. This study is the first systematic genetic characterization of 
all known HRV prototype strains, providing a further taxonomic proposal for 
classification of HRV. We proposed to divide the genus Human rhinoviruses into 
HRV-A and HRV-B.
The final part of the work comprises a phylogenetic analysis of a subset (48) of 
HRV prototype strains and field isolates (12) in the nonstructural part of the genome 
coding for the RNA-dependent RNA polymerase (3D). The proposed division of the 
HRV strains in the species HRV-A and HRV-B was also supported by 3D region. 
HRV-B clustered closer to HEV species B, C, and also to polioviruses than to HRV-
A. Intraspecies variation within both HRV-A and HRV-B was greater in the 3D 
coding region than in the VP4/VP2 coding region, in contrast to HEV. Moreover, 
the diversity of HRV in 3D exceeded that of HEV. One group of HRV-A, 
designated HRV-A’, formed a separate cluster outside other HRV-A in the 3D 
region. It formed a cluster also in the capsid region, but located within HRV-A. This 
may reflect a different evolutionary history of distinct genomic regions among 
HRV-A. Furthermore, the tree topology within HRV-A in the 3D region differed 
from that in the VP4/VP2, suggesting possible recombination events in the evolution 
of the strains. No conflicting phylogenies were observed in any of the 12 field 
isolates. Possible recombination was further studied using the Similarity and 
Bootscanning analyses of the complete genome sequences of HRV available in 
public databases. Evidence for recombination among HRV-A was found, as HRV2 
and HRV39 showed higher similarity in the nonstructural part of the genome. 
Whether HRV2 and HRV39 strains – and perhaps also some other HRV-A strains 
not yet completely sequenced – are recombinants remains to be determined.  
Keywords: molecular epidemiology, human rhinovirus, human enterovirus, 
echovirus 
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TIIVISTELMÄ 
Työn ensimmäinen osa koostuu molekyyliepidemiologisesta tutkimuksesta, jossa 
tutkittiin erään ihmisen enteroviruksen (HEV), echovirus 30:n kliinisiä isolaatteja. 
Tämä tutkimus on osa tutkimusryhmämme toteuttamaa HEV-B virusten 
molekyyliepidemiologiaa tutkivaa sarjaa. Tutkimuksessa mukana olleet kaikkiaan 
129 viruskantaa oli eristetty eri puolella Eurooppaa. Sekvenssianalyysi käsitti kolme 
erillistä genomialuetta; 420 nukleotidin pituisen VP4/VP2-kapsidiproteiineja 
koodaavan osan, koko 876 nukleotidin pituisen VP1-kapsidiproteiinia koodaavan 
geenin sekä 150 nukleotidin pituisen VP1/2A- risteysalueen. Analyysi paljasti 
vallitsevien geneettisten alaryhmien jatkumon yhden päägenotyypin sisällä. 
Aiemmat genotyypit olivat korvautuneet geneettisesti yhtenäisellä alatyypillä, joka 
oli kiertänyt Euroopassa 1970-luvun lopulta lähtien. Muut tutkimusryhmät olivat 
havainneet saman genotyypin myös Pohjois-Amerikassa ja Australiassa. Kuitenkin 
maailmanlaajuisesti muitakin yhtä aikaa kiertäviä genotyyppejä on havaittu. 
Echovirus 30:lla havaittu yhden päägenotyypin vallitsevuus eroaa muista 
enterovirusserotyypeistä, joita on tutkittu molekyyliepidemiologian keinoin. 
Tällaisia ovat esimerkiksi poliovirukset sekä coxsackievirukset B4 ja B5, joilla on 
havaittu useita samanaikaisia geneettisesti eroavia alatyyppejä.   
Työn toisessa osassa ihmisen rinovirusten molekyyliepidemiologiaa tutkittiin 61 
kliinisen isolaatin geneettisellä analyysillä 420 nukleotidin pituisella VP4/VP2- 
kapsidiproteiinialueella. Virusisolaatit oli kerätty alle kaksivuotiaista lapsista 
Tampereen alueella. Kliinisistä isolaateista saadut sekvenssit jakautuivat kahteen 
ennalta tunnettuun fylogeneettiseen pääryhmään. Alaryhmiä muodostui 
vuodenaikaisvaihtelun mukaan. Myös saman epidemiakauden aikana havaittiin 
kiertäneen useita erillisiä serotyypin kaltaisia klustereita. Lisäksi, klusterin havaittiin 
ilmestyneen uudelleen yhden epidemiakauden poissaolon jälkeen. Analysoitujen 
rinoviruskantojen molekyyliepidemiologia näytti monimutkaiselta, joten päätimme 
jatkaa rinovirustutkimuksia. 
Rinovirusten sekvenssianalyysiin oli saatavilla vain viisi aiemmin kokonaan 
sekvensoitua prototyyppikantaa. Sen vuoksi kaikki nimetyt 102 rinovirusten 
prototyyppikantaa sekvensoitiin VP4/VP2-alueelta ja mahdollisuutta rinovirusten 
geneettiseen tyypitykseen tutkittiin. 76 prototyyppikantaa klusteroitui rinovirusten 
geneettiseen ryhmään A (HRV-A) ja 25 ryhmään B (HRV-B). Serotyyppi 87 erosi 
muista rinoviruksista ja klusteroitui enterovirus D- ryhmään. Rinovirusten kliiniset 
isolaatit edustivat 19 erillistä serotyyppiä, kun kriteerinä käytettiin 20% eroavuutta 
nukleotidisekvenssissä VP4/VP2-alueella. Serotyyppien väliset erot rinoviruksilla 
olivat yleensä samaa luokkaa kuin enteroviruksilla on havaittu (noin 20%), mutta 
myös pienempiä, alle 10%, eroja havaittiin. Koska osa rinovirusserotyypeistä on 
geneettisesti hyvin lähellä toisiaan, ehdotamme, että geneettisen tyypityksen 
kriteerinä käytetään ”lähintä prototyyppiä”. Tämä tutkimus oli ensimmäinen 
kaikkien tunnettujen rinovirusprototyyppikantojen systemaattinen geneettinen 
kartoitus ja se tarjoaa pohjan ihmisen rinovirusten taksonomiselle luokittelulle 
kahteen ryhmään HRV-A ja HRV-B.
Työn viimeinen osa käsittelee fylogeneettistä analyysia, jossa oli mukana 48 
rinovirusten prototyyppikantaa sekä 12 kliinistä isolaattia. Tutkittavana 
genomialueena oli ei-strukturaalinen viruksen RNA polymeraasia koodaava 3D-
alue. Rinoviruskannat jakautuivat aiemmin määriteltyihin ryhmiin HRV-A ja HRV-
B myös 3D-alueella. HRV-B klusteroitui geneettisesti lähemmäs enterovirus-B, -C 
ja poliovirusryhmiä kuin HRV-A:ta. Ryhmien sisäinen variaatio sekä HRV-A:ssa 
että HRV-B:ssä oli suurempaa 3D- kuin VP4/VP2-kapsidialueella, toisin kuin 
enteroviruksilla. Lisäksi rinovirusten variaatio 3D:ssa oli suurempaa kuin 
enteroviruksilla. 3D-alueella havaittiin erillinen klusteri, joka kapsidialueella kuului 
HRV-A:han. Se nimettiin HRV-A’:ksi. Tämä havainto saattaa olla seurausta HRV-
A rinovirusten eri genomialueiden erilaisesta evoluutiohistoriasta. Myös HRV-A:n 
fylogeneettisten puiden topologiassa havaittiin eroja kapsidialueen ja ei-
strukturaalialueen välillä, mikä saattaa viitata eri kantojen rekombinaatioon. 
Kuitenkin kaikki 12 tutkittua kliinistä isolaattia klusteroituivat samoin kuin 
kapsidialueella. Mahdollista rekombinaatiota selvitettiin julkisissa tietokannoissa 
saatavissa olevien rinovirusten kokogenomisekvenssien Similarity ja Bootscanning 
–analyyseillä. Todisteita rekombinaatiosta HRV-A:ssa saatiin, kun HRV2 ja HRV39 
osoittivat keskimääräistä suurempaa samankaltaisuutta genomin ei-
strukturaaliosassa.  Ovatko juuri HRV2 ja HRV39 rekombinoituneita kantoja vai 
kenties jotkut muut toistaiseksi sekvensoimattomat HRV-A serotyypit, jää vielä 
selvitettäväksi.   
Avainsanat: Molekyyliepidemiologia, ihmisen rinovirus, ihmisen enterovirus, 
echovirus 
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1 INTRODUCTION 
The most frequent acute illness in humans worldwide is acute respiratory infection. 
The frequent form of it, common cold, is predominantly caused by human 
rhinoviruses (HRVs) (Arruda et al. 1997; Mäkelä et al. 1998). Identification of HRV 
is usually based on detection of viral genome by RT-PCR. This is mainly because of 
the laborious isolation procedure and the large number of HRV serotypes.  Despite 
the common nature of HRV, the laboratory diagnosis of this virus group is generally 
restricted to a genus level of identification and serotyping is not generally 
performed. Thus, very little is known about the incidence and characteristics of 
different HRV serotypes. The genetic features and relationships of a closely related 
genus, enteroviruses, have been extensively studied in recent years. The novel 
genetic typing of enteroviruses (Oberste et al. 1999b) based on the sequence in the 
VP1 coding part of the genome has expanded the possibilities of enterovirus 
research. As a result, several new enterovirus types have been identified. 
Development of antiviral drugs requires information on the molecular features of the 
target group of viruses. HRVs have been recognized as a major cause of an 
economically important disease. As they comprise more than 100 serotypes, new 
information on the genetic relationships of these viruses would be extremely 
important. Furthermore, information on currently circulating HRV strains is very 
limited and needs updating. 
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2 REVIEW OF THE LITERATURE 
2.1 HUMAN PICORNAVIRUSES 
2.1.1 GENERAL ASPECTS 
Picornaviruses are among the smallest RNA-containing animal viruses known. They 
comprise one of the largest and most important virus families of human and 
veterinary pathogens, Picornaviridae. Well known members of picornaviruses 
include polioviruses, human hepatitis A virus, and foot-and-mouth disease virus. 
Headway made in investigating, for example, poliomyelitis and foot-and-mouth 
disease, both of which are medically and economically significant, has contributed 
greatly to the development of modern virology. 
2.1.2  STRUCTURE   
Picornaviruses are nonenveloped particles of about 30 nm in diameter. They possess 
an icosahedral capsid containing 60 copies of each of the four capsid proteins (VP1-
4). The capsid is composed of 12 pentagon-shaped pentamers of five protomers, 
each holding one copy of four structural proteins. The major capsid proteins, VP1 to 
VP3, are folded into eight-stranded antiparallel β-sheets with a jelly-roll topology. 
The β-barrels of VP1 proteins are located around a fivefold axis of symmetry, while 
VP2 and VP3 are located around the threefold axis. VP4, the smallest structural 
protein, is located on the inner surface of the capsid. At the fivefold axis, there is a 
star-shaped plateau surrounded by a circular canyon. The canyon outlines a 
protrusion of five copies of VP1 from the surrounding VP2 and VP3. Beneath the 
canyon floor, within the core of VP1, is a hydrophobic tunnel, a “pocket”. 
(Racaniello 2001). 
2.1.3 GENOMIC STRUCTURE AND EXPRESSION 
The viral genome is a single-stranded, messenger-sense RNA of 7000-8800 nt with a 
single open reading frame (Fig. 1). The basic structure is shared by all picornaviruses. 
There is a short peptide (VPg or 3B) covalently coupled to the 5’ end of the RNA. The 
5’ noncoding region (NCR) is involved in the initiation of translation, directing 
14
ribosomes into the internal ribosome entry site (IRES). The NCR is followed by the 
protein coding region. It encodes a single polyprotein, which is proteolytically cleaved 
into precursor proteins P1, P2, and P3, and thereafter into structural proteins VP1 to 
VP4 (P1 region) and seven nonstructural proteins (P2 and P3). The nonstructural 
proteins include viral proteases (2A, 3C, and 3CD) and the RNA-dependent RNA 
polymerase (3D). In addition, 2C is a helicase, and 2B, 2BC, 3A and 3AB are 
associated with various functions in the replication of the viral RNA. These regions 
are followed by a short 3’NCR and a poly-A tail. The 3’NCR has a role in initiating 
the synthesis of negative-strand RNA. (Racaniello 2001). 
Figure 1. The Picornavirus genome. 
VPg
5’
1000 2000 3000 4000 60005000 7000    nt
An
NCR
VP4
VP2 VP3 VP1 2A 2B 2C 3A
3B
3C 3D NCR
P1 P2 P3
CAPSID PROTEINS NONSTRUCTURAL PROTEINS
3’
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HRVs infect cells of the nasopharyngeal region in vivo. Replication takes place in 
the cytoplasm of the host cell. In order to enter the cell, viruses attach to a cell 
surface receptor. Rhinoviruses use either intercellular adhesion molecule 1 (ICAM-
1) (major receptor group) (Greve et al. 1989; Staunton et al. 1989; Tomassini et al. 
1989) or a member of the low-density lipoprotein (LDL) receptor family (minor 
receptor group) (Hofer et al. 1994; Gruenberger et al. 1995; Marlovits et al. 1998). 
ICAM-1 is a member of the immunoglobulin superfamily. Cryoelectron microscopy 
and image reconstruction analysis for HRV3 (Xing et al. 2003), HRV14 (Kolatkar et 
al. 1999), and HRV16 (Olson et al. 1993) have revealed that the binding site of 
ICAM-1 is at the base of the canyon. The LDL receptor family includes the LDL 
receptor itself, the very low-density lipoprotein (VLDL) receptor and the LDL-
receptor-related protein. They act as mediators in the transport of lipoproteins into 
the cells by receptor-mediated endocytosis. The VLDL receptor footprint, located at 
the star-shaped plateau of the icosahedral fivefold axis, is formed by the BC and HI 
loops of VP1 (Hewat et al. 2000).  
Upon attachment to the cellular receptors, conformational changes in the viral capsid 
are triggered. The uncoating process leads to a release of viral RNA into the 
cytoplasm. The major and minor receptor group viruses are proposed to have 
different mechanisms for uncoating. HRV14, binding to ICAM-1, rapidly uncoats 
without the participation of a cellular machinery (Greve et al. 1991; Casasnovas and 
Springer 1994). Release of HRV2 RNA, in contrast, is mediated by clathrin-
dependent internalization of the virus into acidic endosomal compartments 
(Neubauer et al. 1987; Prchla et al. 1994; Schober et al. 1998; Snyers et al. 2003). 
The viral RNA is translated in the cytoplasm by exploiting the cellular machinery. 
The viral proteins are synthesized first to obtain the RNA-dependent RNA 
polymerase that previously was nonexistent in the cell. The complete viral protein 
coding region is translated into a long polyprotein precursor, which is co-
translationally cleaved into the intermediates P1, P2, and P3 by two proteinases, 2A 
and 3C/3CD. P2 and P3 proteins are cleaved into seven nonstructural proteins in 
addition to several intermediates acting in RNA replication and polyprotein 
processing.  The viral RNA is then used as a template for synthesis of negative-
strand RNA by polymerase 3D. This strand is used in the replication complex in the 
synthesis of positive-strand copies, which in turn are translated into viral proteins or 
encapsidated into the assembling virions. The assembly of new virions begins with 
P1 cleavage into VP0, VP1, and VP3. 
VP0 is further cleaved to VP4 and VP2 in the process called maturation cleavage. The 
new infectious virions are assembled and released from the cell. (Racaniello 2001).  
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One replication cycle of rhinoviruses is typically completed in 10-12 hours, but 
depending on the type of virus can take up to 17 hours. New virus progeny, generally 
detected in 5-7 hours, can appear as late as 9 hours. (Stott and Killington 1972). 
2.1.4 TAXONOMY AND SUBGROUPING 
The family Picornaviridae contains nine genera according to the most recent 
taxonomy (Stanway et al. 2005). These genera are: Enterovirus, Rhinovirus, 
Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, Kobuvirus, and 
Teschovirus (Fig. 2). Each genus is further divided into species containing one or 
more antigenically distinct serotypes. Currently the total number of serotypes in 
Picornaviridae is well beyond 200. The taxonomy of Picornaviridae is changing 
and new tentative species as well as new, partially characterized serotypes have been 
proposed to be assigned to the family (Stanway et al. 2005).  
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Figure 2. Neighbor-joining tree depicting genetic relationships of the family 
Picornaviridae in the capsid protein coding region. Numbers indicate Bootstrap 
values (1000 replicates). LV, Ljungan virus; HPeV, Human parechovirus, BKV, 
Bovine kobuvirus; AIV, Aichi virus; PEV-A, Porcine enterovirus A; HEV-B, Human 
enterovirus B, PV, Poliovirus; HEV-C, Human enterovirus C; HRV-A, Human 
rhinovirus A, HRV-B, Human rhinovirus B, SEV-A, Simian enterovirus A, HEV-A, 
Human enterovirus A, BEV, Bovine enterovirus; PEV-B, Porcine enterovirus B;
HEV-D, Human enterovirus D; PTV, Porcine teschovirus, EMCV, 
Encephalomyocarditis virus, ThV, Theilovirus, ERBV, Equine rhinitis B virus,
FMDV, Foot-and-mouth disease virus; ERAV, Equine rhinitis A virus; HAV, 
Hepatitis A virus; AELV, Avian encephalomyelitis-like virus. Reprinted from 
Stanway et al. (2005) with permission from Elsevier. Only in printed version.
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2.1.4.1 CLASSIFICATION OF ENTEROVIRUSES 
The traditional classification of HEVs is based on shared biological properties, i.e. 
hosts and pathogenicity in experimental animals. The official classification comprises 
68 serotypes (Stanway et al. 2005). However, the enterovirus genus currently consists 
of more than 100 separate members, several of which have not been officially 
classified yet. The new serotypes have been assigned based on genetic features in the 
VP1 capsid protein coding gene. HEVs are further divided into the species HEV-A to 
HEV-D. Polioviruses (PVs) are included in HEV-C (Table 1).  
Table 1. Members of the Enterovirus genus 
Species (number of serotypes) Representatives 
Human enterovirus  A (13) Human coxsackieviruses (CV) A2-A8, A10, A12, A14, A16 
 Human enterovirus  (EV) 71, 76 
Human enterovirus  B (41) Human coxsackievirus A9, B1-6 
 Human echovirus (E) 1-7, 9, 11-21, 24-27, 29-33 
 Human enterovirus 69, 73-75, 77, 78 
Human enterovirus  C (9) + 
poliovirus  (3) 
Human coxsackieviruses A1, A11, A13, A17, A19-22, A24, 
Human polioviruses  (PV) 1-3 
Human enterovirus D (2)  Human enterovirus 68, 70 
unclassified enteroviruses  
(> 50)  
    
Human echo (Enteric Cytopathogenic Human Orphan) –viruses were thus named, 
since after the first isolations their relationship to human disease was unknown, and 
they also failed to produce illness in laboratory animals (Committee on the ECHO 
Viruses 1955). They have subsequently been classified into HEV-B (Table 1). 
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2.1.4.2 SUBGROUPING OF HUMAN RHINOVIRUSES 
2.1.4.2.1 CELL GROWTH 
In early studies, the rhinovirus strains were classified as H or M depending on their 
growth properties in different cell lines (Taylor-Robinson and Tyrrell 1962; 
Hilleman 1967). H strains are able to replicate only in human embryonic kidney 
cells, while M strains grow in both human and monkey kidney cells. The separation 
based on growth properties has subsequently been inaccurate, with exceptions found 
in both classes (Mufson et al. 1965; Phillips et al. 1965; Douglas et al. 1966).  
2.1.4.2.2 RECEPTOR SPECIFICITY 
The first classification of rhinoviruses into two receptor groups was based on 
competitive binding assays between pairs of serotypes before the receptors were 
known (Abraham and Colonno 1984). When the ICAM-1 was identified as a major 
receptor, 101 rhinovirus serotypes were divided into receptor groups (Uncapher et 
al. 1991). A total of 91 serotypes belonged to the major group, while 9 serotypes 
(HRV1 subtypes A and B, HRV2, HRV29, HRV30, HRV31, HRV44, HRV47, 
HRV49, and HRV62) were members of the LDL-receptor-using minor group. 
HRV87 could not be classified into either of these groups. Its attachment to HeLa 
cells was inhibited by pretreatment with neuraminidase, and thus, it was suggested 
that this virus uses sialic acid as a receptor (Uncapher et al. 1991). Confirmation of 
the receptor groups was achieved when inhibitory activities of soluble ICAM-1 
molecules were tested against all  rhinoviruses (Crump et al. 1993). All major-group 
rhinoviruses, except HRV23 and HRV25, were inhibited by soluble ICAM-1. 
Neither the replication of the minor-group viruses nor that of HRV87 was affected. 
Recently, HRV23 and HRV25 have been shown to belong to the minor receptor 
group (Vlasak et al. 2005). Furthermore, the ICAM-1-using serotypes have been 
demonstrated to have preference over the natural variants of the molecule (Xiao et 
al. 2004). HRV14 binds to ICAM-1 only transiently but forms a stable complex with 
a variant ICAM-1Kilifi, whereas HRV16 does not bind to ICAM-1Kilifi.
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2.1.4.2.3 SENSITIVITY TO ANTIVIRAL AGENTS 
Considerable efforts have been directed at developing antiviral therapy against 
rhinovirus infection. Over the course of these studies, several structurally unrelated 
antiviral compounds have been shown to inhibit replication of rhinoviruses. The 
binding site for most of the antiviral agents is a hydrophobic pocket in the capsid 
protein VP1. A systematic, multivariate analysis of 100 rhinovirus serotypes tested 
against a panel of 15 antiviral compounds divided rhinoviruses into two antiviral 
groups. Antiviral group A included 33 serotypes with a greater than average 
susceptibility to elongated antiviral compounds such as WIN51711. Antiviral group B 
contained 67 serotypes susceptible to structurally shorter antiviral agents, including 
chalcone, dichloroflavan, and R61837. (Andries et al. 1990; Andries et al. 1991). 
2.1.4.2.4 ANTIGENIC DIFFERENCES 
A systematic analysis of antigenic relationships of 90 rhinovirus serotypes revealed 
that 50 of these serotypes could be divided to 16 antigenic groups (Cooney et al. 
1982). Each of these groups contained 2-10 antigenically related serotypes. 
Reciprocal neutralization was observed for virus pairs HRV1A-HRV1B, HRV2-
HRV49, HRV3-HRV14, HRV9-HRV32, HRV12-HRV78, HRV13-HRV41, 
HRV15-HRV74, HRV29-HRV44, and HRV36-HRV58 (Cooney et al. 1973; 
Schieble et al. 1974; Cooney et al. 1982). One-way cross-reactions have been 
reported for pairs HRV5-HRV42, HRV6-HRV14, HRV9-HRV67, HRV11-HRV40, 
HRV11-HRV74, HRV17-HRV42, HRV17-HRV70, HRV22-HRV61, HRV32-
HRV67, HRV36-HRV50, HRV36-HRV89, HRV39-HRV54, HRV40-HRV56, 
HRV60-HRV38, HRV66-HRV77, and HRV76-HRV11 (Cooney et al. 1973; 
Calhoun et al. 1974; Cooney et al. 1982). Heterotypic antibody responses have also 
been demonstrated in humans after natural infection. Natural infection with one of 
the related serotypes (HRV1A and HRV1B, HRV2 and HRV49, HRV23 and 
HRV30 or HRV29, and HRV44 and HRV62) raised antibodies also against another 
virus and was suggested to provide cross-protection (Mogabgab et al. 1975).  
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2.1.4.2.5 GENETIC RELATIONSHIPS 
A complete genome sequence of a HRV was first published in 1984 for HRV14 
(Stanway et al. 1984) and one year later for HRV2 (Skern et al. 1985) (Table 3). The 
first study on the genetic relationships of HRV was published in 1986 by (Al-Nakib 
et al. 1986) and colleagues. This study was based on cDNA hybridization. Of the 54 
serotypes investigated, HRV3, HRV4, HRV17 and HRV72 were suggested to be the 
closest relatives of HRV14. The next complete genome sequence was published for 
HRV89, after which the molecular relationships of the three known complete 
genome sequences of HRV were compared (Duechler et al. 1987). Extensive 
similarity between HRV89 and HRV2 was found, while HRV14 appeared to be 
more distant. The division into two genetic clades was corroborated in comparisons 
of partial 5’NCR of an additional 10 prototype strains (Mori and Clewley 1994). 
Altogether 39 HRV serotypes were analyzed in the 5’NCR and clustering into two 
major clades confirmed (Andeweg et al. 1999). Furthermore, HRV87 was found to 
be the most divergent, forming a clade of its own. The first wider study on genetic 
relationships of HRV in the capsid coding region was published in 1995 by Horsnell 
and colleagues. This study dealt with partial sequences in the VP2 capsid protein 
coding region, including the immunogenic site NImII, of 21 HRV prototype strains. 
The two major genetic clades were substantiated.  Eighteen of the 21 sequenced 
serotypes were shown to belong to the HRV2-related group, while three serotypes 
formed the HRV14-related group. Thus far, eight complete HRV genomes have 
been sequenced (Table 2). 
Table 2. Human rhinovirus (HRV) prototype strains for which a complete genome 
sequence has been published. 
HRV prototype strain Reference 
HRV1B Hughes et al. 1988  
HRV2 Skern et al. 1985 
HRV9 Leckie 1987 
HRV14 Stanway et al. 1984 
HRV16 Lee et al. 1995 
HRV39 Harris and Racaniello 2005 
HRV85 Stanway 1989 
HRV89 Duechler et al. 1987 
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2.1.5 EVOLUTION OF PICORNAVIRUSES  
2.1.5.1 POINT MUTATIONS 
The evolution of RNA viruses is driven by two mechanisms, mutation and 
recombination. Mutations are based on the errors in the replication of the RNA 
catalyzed by the virus encoded RNA-dependent RNA polymerase (Holland et al. 
1992). Since the polymerase lacks proof-reading activity, changes in the viral 
genome occur frequently. Rate of spontaneous mutations for enteroviruses have 
been estimated to be one mutation per genome per replication (Drake and Holland 
1999). As a result, virus populations are genetically heterogeneous (Holland et al. 
1982). These mixtures of genetic variants are called quasi-species (Holland et al. 
1992). Most mutations generate synonymous codons which are unlikely to have 
effects on the genetic fitness of the virus. Selective environmental conditions may, 
however, shift the equilibrium of the virus population, providing an opportunity for 
any variant to compete with the dominant virus (Agol 1997). Enterovirus evolution 
is believed to occur primarily by genetic drift. Genetic drift develops, when a sample 
of quasi-species is amplified after passage through a genetic bottleneck (Holland and 
Domingo 1998). Most of the bottlenecks have been suggested to arise during 
replication within the human intestine (Hughes et al. 1988; Kinnunen et al. 1990). 
Neutral mode of evolution may also occur during person-to-person transmission of 
the virus. RNA viruses have been postulated to evolve conservatively, not adapting 
but merely changing (Sala and Wain-Hobson 2000). 
2.1.5.2 RECOMBINATION 
Another important means to extend the range of genetic variants for picornaviruses 
is recombination. During synthesis of the negative strand strand-switching occurs, 
frequently leading to replicative recombination (Agol 1997).  Another suggested 
mechanism for recombination is nonreplicative, by strand-breaking and re-joining of 
RNA molecules by trans-esterification (Gmyl et al. 1999; Gmyl et al. 2003). 
Recombination of polioviruses was first discovered in the 1960s (Hirst 1962; Ledinko 
1963). Experimental crosses of closely related strains have been shown to yield >1% 
recombinant progeny from a single growth cycle (Argos et al. 1984). Enteroviruses 
participate in intraserotypic and interserotypic homologous recombination (Santti et al. 
1999; Andersson et al. 2002; Oprisan et al. 2002; Lindberg et al. 2003; Lukashev et al. 
2003b). However, recombination has only been detected within species. Preferential 
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recombination breakpoints have been identified in the nonstructural part of the 
genome and at the 5’NCR-P1 junction (Santti et al. 1999; Andersson et al. 2002; 
Oprisan et al. 2002; Lindberg et al. 2003; Lukashev et al. 2003b). Recombination 
within the capsid coding region is rare, but has been reported for polioviruses among 
the OPV strains in the VP1 capsid protein coding region (Martin et al. 2002; 
Blomqvist et al. 2003). Recombination has been proposed to be a common trend in 
enterovirus genetics (Lukashev 2005). Recombination has not, however, been reported 
for rhinoviruses.  
2.2 HUMAN RHINOVIRUSES 
2.2.1 DESIGNATION OF DISTINCT SEROTYPES 
Rhinovirus research commenced at the Common Cold Research Unit in England in 
the early 1950s (Tyrrell 2002). As serologically different strains were isolated, 
epidemiological data accumulated rapidly (Taylor-Robinson and Tyrrell 1962). The 
National Institute of Allergy and Infectious Diseases (NIAID) and the World Health 
Organization (WHO) initiated a Rhinovirus Collaborative Programme for the 
classification of rhinovirus strains. The antigenic relationships of a large collection 
of candidate rhinovirus strains were studied by a reciprocal neutralization test with 
virus strains and sera by a reference laboratory, the Children’s Hospital in 
Columbus, Ohio. In addition, each laboratory submitting new strains was to test 
their candidate strains against all available sera. This procedure ensured two 
independent tests for new virus strains. HRVs were assigned a number and a 
prototype strain in three phases. The first phase assigned rhinoviruses from HRV1 to 
HRV55 (Kapikian et al. 1967). HRV1 had been shown to have two subtypes, 
HRV1A and HRV1B.  
In the second phase, rhinoviruses were numbered from HRV56 to HRV89 (Kapikian 
et al. 1971). The third phase assigned rhinovirus serotypes HRV90 to HRV100 
(Hamparian et al. 1987). After the Rhinovirus Collaborative Program, only one 
strain, Hanks, has been proposed as a new serotype (Gwaltney et al. 1978). 
However, in recent years, the serotypes of newly isolated HRV strains have not 
been systematically defined. Therefore, it is possible that new serotypes exist. 
As mentioned above, antigenic cross-reactions between serotypes occur, and some 
were noticed already during the numbering phases but were considered to be due to 
nonspecific inhibitors (Conant and Hamparian 1968). 
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2.2.2 GENERAL CHARACTERISTICS 
Rhinoviruses share the basic properties of all viruses belonging to the family 
Picornaviridae. They are most closely related to enteroviruses (Fig. 2). Rhinoviruses 
and enteroviruses form two of the largest groups of Picornaviruses (Stanway et al. 
2005). The classic difference observed between these virus genera has been their 
capacity to persist in an acidic environment. Enteroviruses have traditionally been 
thought to endure the acidic conditions of the stomach in order to be able to proceed 
to gut, where they replicate. Rhinoviruses, by contrast, infect primarily the tissue of 
the upper respiratory tract, and therefore do not need to withstand acidic conditions. 
The optimal pH for rhinoviruses ranges from 6.0 to 8.0. Below pH 6.0, rhinoviruses 
are readily inactivated. Infectivity of HRV14 has been shown to decrease at pH 5.0 
in 20 minutes and totally disappear at pH 3.0 in 10 seconds. However, the 
inactivation in acidic conditions is dependent on the temperature. At pH 5.0, HRV14 
loses 99% of its infectivity almost immediately at 24°C, but at 0°C remains infective 
for more than 5 minutes (Hughes et al. 1973). The molecular basis of the difference 
in acid sensitivity between entero- and rhinoviruses remains unknown. Irreversible 
conformational changes at both the surface of the virus and in the inner part of the 
capsid have been reported for HRV14 in acidic conditions (Giranda et al. 1992). 
However, adaptation to an acidic environment through mutation has been achieved 
by serial exposure of the viruses to pH 4.5 followed by passaging in HeLa cells 
(Skern et al. 1991).
The optimal temperature for rhinovirus isolation from clinical specimens is 33°C. 
However, their infectivity has been shown to be maintained at 24-37°C (Hendley et 
al. 1973) as well as at 6°C and 23°C (Reagan et al. 1981). They can survive on 
environmental surfaces for hours to days. In contrast to enteroviruses, most 
rhinoviruses are thermostable (Dimmock 1967). In laboratories, rhinovirus stocks, 
like the stocks of most viruses, are stored frozen. Their activity can be re-established 
after years of freezing (Couch 2001). 
Rhinoviruses are resistant to ether, chloroform, fluorocarbon, and detergents due to 
the lack of a lipid envelope. Alcoholic disinfectants are not effective against 
rhinoviruses. (Couch 2001). Organic acids have been shown to have virucidal 
effects when added to hand cleansers (Turner et al. 2004). A mixture of peroxygen 
compounds and organic acids is generally used for virus inactivation in laboratories. 
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2.2.3 ANTIGENIC STRUCTURE AND NEUTRALIZATION MECHANISMS 
The locations of neutralizing antigenic epitopes have been determined for HRV2 
and HRV14 by analyzing neutralization-resistant mutants (Table 3). The epitopes 
were found in hypervariable regions of the capsid proteins located at the highest 
points of the virus surface. HRV14 was shown to have four different epitopes 
involved in antibody-mediated neutralization (Sherry and Rueckert 1985; Sherry et 
al. 1986), while three sites were involved in neutralization of HRV2 (Skern et al. 
1987; Appleyard et al. 1990). Site A in HRV2 closely resembles the NImIA site of 
HRV14. Moreover, the VP2 component of site B of HRV2 has a partial analog in 
the NImII site of HRV14 (Skern et al. 1987; Appleyard et al. 1990; Verdaguer et al. 
2000). Antibody-driven neutralization of rhinovirus infectivity may occur through 
several mechanisms, as reviewed by Smith 2001. These mechanisms are aggregation 
of viruses, stabilization of the viruses and subsequent prevention of uncoating, 
induction of conformational changes in the capsid, and steric blocking of cellular 
attachment, the last of  which is considered the main mechanism. 
Table 3. Amino acid residues defining the antigenic sites in Human rhinovirus 
(HRV) -2 and -14.* 
    VP1 VP2 VP3 
HRV2     
Site A  85,86,92   
Site B  260,262,264,265,272,274 159,161,163,164 59, 64 
Site C   214,236,238  
HRV14     
NImIA  91,95   
NImIB  83,85,138,139   
NImII  210 156,158,159,161,162  
NImIII  287  72,75,78,203 
*Adapted from Verdaguer et al. (2000) 
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2.2.4 RHINOVIRUS INFECTION 
2.2.4.1 NATURAL COURSE AND CLINICAL PICTURE  
Transmission of rhinovirus infection occurs through three routes: aerosols, fomites, 
and personal contact (Jennings and Dick 1987). Infection is initiated as the virus 
enters the nose or the eye, where it passes down the lacrimal duct. Rhinoviruses 
infect cells of the respiratory tract. They replicate mainly in the ciliary epithelial 
cells of the nasal mucosa and, to a lesser extent, the oral cavity and throat (Cate et al. 
1964). Rhinoviruses have been suggested to infect cells of lower respiratory tract 
less often those of the upper respiratory tract. However, bronchial epithelial cells 
have also been shown to be susceptible to HRV (Papadopoulos et al. 1999; Hayden 
2004). The amount of HRV needed to infect a human is very small, it is as little as 
one tissue culture infectious dose50 (TCID50).
Rhinoviruses are believed not to infect the intestine, attempts to infect the intestinal 
tract of adult volunteers have failed (Cate et al. 1967).  Rhinoviremia is considered 
rare, although occasionally observed in fatal cases of infants (Urquhart and Stott 
1970; Las Heras and Swanson 1983) and recently in several cases of asthma 
exacerbations in children (Xatzipsalti et al. 2005).  
Rhinovirus infection mainly manifests as acute upper respiratory infection, generally 
known as the common cold. HRVs are responsible for most episodes of the common 
cold in all age groups (Arruda et al. 1997; Mäkelä et al. 1998). The common cold 
caused by HRV is clinically similar to that caused by other virus groups. The 
incubation period is 1-4 days, and the symptoms usually peak 3-7 days after the 
onset of infection (Couch 2001). Typical symptoms include sore throat, sneezing, 
nasal obstruction, and nasal discharge. Other symptoms can be hoarseness, cough, 
headache, malaise, and fever (Couch 2001). The duration of the illness is generally 
7-14 days, but it can last longer. Viral shedding in nasal secretions can continue for 
up to three weeks, with the amount of virus in nasal secretions being small in the 
early days of infection (Gwaltney 2002a). Rhinoviral RNA can be detected in nasal 
secretions weeks after illness (Jartti et al. 2004). Symptoms of rhinovirus infection 
are believed to be partly caused by the induction of pro-inflammatory cytokines 
such as kinins, leukotrienes, histamines, interleukin-1, interleukin-6, interleukin-8, 
tumor necrosis factor, and RANTES (Naclerio et al. 1988; Noah et al. 1995; 
Schroth et al. 1999). Rhinovirus infection elicits serotype-specific immunity. 
Neutralizing antibodies have emerged in serum 14-17 days after inoculation, and 
peak titers were reached at 4-5 weeks following an experimental HRV15 infection  
(Douglas 1970). The titers were proposed to persist for at least 1-3 years. 
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Rhinovirus infection can range from a mild, self-limiting respiratory nuisance to a 
more severe outcome. Common complications of infection include acute otitis 
media (Arola et al. 1988; Pitkäranta et al. 1998; Vesa et al. 2001; Nokso-Koivisto et 
al. 2004), acute community-acquired sinusitis (Pitkäranta et al. 1997; Puhakka et al. 
1998; Pitkäranta et al. 2001), and exacerbations of multiple types of pre-existing 
chronic respiratory diseases, such as asthma (Johnston et al. 1995; Gern 2002), 
chronic obstructive pulmonary disease (Greenberg 2002) and cystic fibrosis (Smyth 
1995). Especially in children, rhinoviruses are often associated with such lower 
respiratory infections as bronchiolitis and pneumonia (Papadopoulos et al. 2000; 
Hayden 2004). Furthermore, rhinovirus infections can lead to severe or even fatal  
pneumonia in immunocompromised patients (Ghosh et al. 1999). 
While rhinoviruses replicate in the upper respiratory pathways, enteroviruses 
replicate in the gut. Enteroviruses cause a wide range of diseases (Melnick 1996), 
with both individual and temporal variation. Most infections are mild or subclinical, 
proceeding over the course of several weeks. Rare cases, however, result in severe 
illness or even death. The clinical features of enteroviral diseases include 
poliomyelitis and other neurological disorders like meningitis, myocarditis, 
conjunctivitis, uveitis, skin and mucosal eruptions, diarrhea, generalized infection in 
newborns, and the common cold. Enteroviruses usually cause acute illnesses, but 
they have also been associated with such chronic diseases as dilated cardiomyopathy 
and type 1 diabetes (Hyöty et al. 1995; Dahlquist et al. 2004; Ylipaasto et al. 2004).  
2.2.4.2 OCCURRENCE  
Rhinoviruses infect humans of all ages, with children being the most susceptible 
(Cohen et al. 1997). Almost all children are reported to have experienced at least one 
rhinovirus infection by the age of two years (Blomqvist et al. 2002a). In the elderly, 
rhinovirus infections manifest as prolonged disease and lower tract symptoms 
(Hayden 2004). Exposure to cold and “chilling” did not appear to have a role in the 
etiology of the common cold in experimental infections (Douglas 1968). By 
contrast, significant psychosocial stress is likely to increase the occurrence and 
severity of the clinical symptoms of HRV infection (Cohen et al. 1997; Takkouche 
et al. 2001). Rhinoviruses cause infections year-round. The peak prevalence periods 
are, however, early fall and late spring months in the northern hemisphere (Cohen et 
al. 1997; Nokso-Koivisto et al. 2004). Enterovirus infections are most prominent in 
late summer and early fall (Melnick 1996). 
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2.2.4.3. TREATMENT  
There is no specific treatment for rhinovirus infections. Several different approaches 
have been applied in the effort to find a treatment. These can be divided into 
symptomatic management aimed at improving the functional status of the patient, 
pharmacological treatment aimed at reducing the risk of complications, and antiviral 
agents aimed at reducing the concentration of virus, thus decreasing the likelihood 
of spread of the infection. 
Symptomatic and pharmacological approaches include vitamin C (Schwartz et al. 
1973), and Echinaceae extracts (Turner et al. 2000a; Turner et al. 2005). 
Anticholinergic compounds are directed against rhinorrhea produced by activation 
of the parasymphathetic nervous system (Gaffey et al. 1987a; Gaffey et al. 1988a).  
Antihistamines have been used to investigate the effect of blocking of the H1
receptor against HRV colds (Gaffey et al. 1987b; Gaffey et al. 1988b; Gwaltney et 
al. 1996). Anti-inflammatory drugs with analgesic and antipyretic properties have 
also been tested (Hsia et al. 1989; Sperber et al. 1992), as have glucocorticoid 
steroids (Farr et al. 1990; Gustafson et al. 1996). In addition, several combinations 
of drugs from different groups have been evaluated. None of the above-mentioned 
compounds has proven a drug of choice for rhinovirus infections. Although some 
symptomatic efficacy has been shown, the common cold could not be prevented or 
cured with these drugs.  
Antiviral drug research has produced new candidate rhinovirus drugs.  Interferon-
alpha (Hayden and Gwaltney 1984; Douglas et al. 1986), interferon-beta (Sperber et 
al. 1989) and zinc salts (Geist et al. 1987; Turner and Cetnarowski 2000b; Turner 
2001) were the first antivirals tested. The most promising group at the moment is the 
capsid stabilizers, including pleconaril (Kaiser et al. 2000; Hayden et al. 2003a). 
However, the oral formulation had drug interactions due to the induction of CYP3A 
activity, leading to a reduction in the effectiveness of oral estrogen-based 
contraceptives, and thus, regulatory approval was not granted. Pleconaril is currently 
available on a compassionate use basis (Hayden 2004). Soluble ICAM-1 receptor 
molecules have also been tested, and tremacamra (Turner et al. 1999) reduced the 
severity of rhinoviral colds. The third group of potential antiviral drugs against 
rhinovirus infections are 3C protease inhibitors, including ruprintrivir (Hayden et al. 
2003b). Antiviral treatment alone may cure the colds, but combining antivirals with 
selected therapeutic agents that block inflammatory pathways appears promising 
(Gwaltney 2002b). 
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2.2.5  LABORATORY DIAGNOSIS 
2.2.5.1 VIRUS ISOLATION AND IDENTIFICATION OF RHINOVIRUS 
SEROTYPES 
Traditionally, rhinoviruses have been detected in laboratories by isolation in cell 
culture (Couch 1992). Cell lines suitable for rhinovirus replication are derived from 
human or other primate tissue. This tissue specificity is affected by the presence of 
receptors on cell surfaces (Colonno et al. 1986). Recommendations for rhinovirus 
isolation are based on experience from early isolation attempts. Optimal culture 
conditions include a medium pH of 7.0-7.2, an incubation temperature of 33°C, and 
slow rotation of cultures (Couch 1992). Replication of the viruses is detected by 
appearance of cytopathic effects (CPEs). The isolation process followed by a 
subculture, including acid-sensitivity testing, is tedious and laborious, and is not 
generally attempted.  
Identification of the serotype of isolated rhinovirus strains can be achieved by 
applying a neutralization test using a hyperimmune antisera. The test can be 
performed using a microneutralization assay with intersecting antiserum pools. The 
standard for serological identity of an unknown rhinovirus strain is neutralization of 
virus concentrations ranging from 10 to 300 TCID50 by 20 units of antibody. The 
neutralization is carried out at 33°C for two hours. Completion of the assay takes 4-6 
days. (Gwaltney et al. 1966; Couch 1992). The large number of serotypes and the 
laborious nature of the assay have hampered its use in rhinovirus diagnosics. 
2.2.5.2 RT-PCR METHODS 
Reverse transcriptase polymerase chain reaction (RT-PCR) has been widely used in 
rhinovirus detection since its introduction in the late 1980s (Gama et al. 1988; Gama 
et al. 1989; Hyypiä et al. 1989; Torgersen et al. 1989). Several RT-PCR applications 
have been described. Most of the rhinovirus RT-PCR assays take advantage of short, 
highly conserved stretches of nucleotides in the 5’NCR as the binding sites for 
oligonucleotide primers.  
These assays have proven to be highly sensitive, but they do not differentiate 
rhinoviruses from enteroviruses. An extra step, such as analysis of restriction 
fragment length polymorphism (Torgersen et al. 1989), hybridization with 
rhinovirus-specific probes (Hyypiä et al. 1989; Johnston et al. 1993; Halonen et al. 
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1995; Blomqvist et al. 1999; Lönnrot et al. 1999; Andreoletti et al. 2000; Jenison et 
al. 2001), sequencing of PCR amplicons (Mori and Clewley 1994; Deffernez et al. 
2004), semi-nested PCR (Ireland et al. 1993), or nested PCR with rhinovirus-
specific primers (Andeweg et al. 1999; Steininger et al. 2001), is needed for 
differentiation between rhinoviruses and enteroviruses. Amplicon size can be used 
for differentiation when the RT-PCR is performed from the 5’NCR to the capsid 
coding region VP4 or VP2 (Olive et al. 1990). The binding site in VP2 is, however, 
variable leading to mismatching and reduced sensitivity (Santti et al. 1997; Hyypiä 
et al. 1998). The most recent application for rapid rhinovirus detection has been real-
time PCR (Dagher et al. 2004; Kares et al. 2004).  
2.3 MOLECULAR EPIDEMIOLOGY 
2.3.1 DEFINITION AND GOALS 
The glossary of molecular medicine defines molecular epidemiology as “the 
application of molecular biology to the answering of epidemiological questions” 
(Cambridge Healthtech Institute 2005). Another definition for molecular 
epidemiology is “epidemiology that focuses on measurements of molecular 
features” (National Cancer Institute 2005). Molecular epidemiology involves the 
integration of molecular biomarkers into population-based studies. The International 
Molecular Epidemiology Task Force (1998) has defined molecular epidemiology as 
“a science that focuses on the contribution of potential genetic and environmental 
risk factors, identified at the molecular level, to the etiology, distribution, and 
prevention of disease within families and across populations". Molecular 
epidemiology has been used in the examination of patterns of changes in DNA to 
implicate particulate carcinogens. The use of molecular markers to predict which 
individuals are at highest risk for a disease has also served as an example of 
molecular epidemiology (Cambridge Healthtech Institute 2005). The term molecular 
epidemiology has frequently been applied in microbiological studies.  
In microbiology and virology, molecular epidemiology means connecting certain 
genomic features of the pathogens to the distribution of related strains. The 
virological glossary defines molecular epidemiology as “the use of nucleotide 
sequence information to study the diversity and distribution of virus populations” 
(Microbiology @ Leicester 2004). Molecular epidemiological use of sequence 
information comes close to phylogenetics, which aims to estimate relationships and 
divergence of related sequences and to understand their past evolution.   
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2.3.2  METHODS AND LIMITATIONS 
Molecular methods, such as genome amplification, restriction fragment length 
polymorphism, sequencing, and comparison of genetic information, have been 
widely used to elucidate the epidemiology of several viruses. Computerized analysis 
of the nucleotide and amino acid sequences can be used to infer phylogenetic 
relationships. The first step in the reconstruction of molecular phylogenetic 
relationships is generation of multiple sequence alignment of the selected sequences. 
The next step is mathematical modeling to describe the evolution of the sequences. 
Finally, a statistical method is applied to generate branching order and branch 
lengths best describing the sequence phylogenies. There are approximately 200 
program packages using several different algorithms based on various evolutionary 
assumptions. Only some of the existing methods are discussed here.  
The alignment of sequences can be performed with several programs. A commonly 
used global alignment program is ClustalX (Thompson et al. 1997), which uses a 
progressive method of clustering. The program creates a guide tree using the 
Neighbor-joining method (NJ) (Saitou and Nei 1987). Possible problems in 
alignment may be due to sequences of variable lengths (Palacios et al. 2002b). 
Another alignment program is the PileUp component of the GCG (Genetics 
Computer Group Inc., USA) program, which implements a simplified version of the 
Feng and Doolittle (1996) algorithm. This alignment tool can deal with terminal 
gaps. However, it assumes a molecular clock where mutations occur at the same rate 
in all sequences. This assumption may hold in a situation of very closely related 
sequences, but it poses limitations on the general use of the method.      
The mathematical models for describing evolution can be divided into character- 
based and distance-based methods. Widely used character-based methods are 
maximum likelihood (ML) and maximum parsimony. Probabilistic likelihood 
techniques are based on the likelihood of a certain tree explaining the sequence data 
set. ML is statistically well founded, and a model of evolution is included in the 
analysis with ML. It is considered one of the most powerful methods of phylogenetic 
reconstruction. The major disadvantage of this method is that it is computationally 
intense. It can also be fooled by a high level of homoplasy, i.e. similarity between not 
homologous sequences. Quartet puzzling is a method of quartet-based maximum 
likelihood (Strimmer 1996). Maximum parsimony infers a phylogenetic tree by 
minimizing the total number of evolutionary steps required to explain a given data set. 
The main drawback of this method is that is underestimates the actual number of 
changes. Moreover, it does not use all sequence information (only informative sites), 
does not correct for multiple mutations (no model of evolution), does not provide 
information on branch lengths, and is sensitive to codon bias. 
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The distance-based methods calculate the distances between each pair of sequences 
and find a phylogenetic tree that reflects these distances. Distance methods in 
general use have been the Unweighted Pair Group Arithmetic Mean (UPGMA) 
(Sokal 1958) and currently the most popular NJ (Saitou and Nei 1987). The 
UPGMA is based on clustering of the sequences by similarity. The principle of NJ is 
to find pairs of neighbors that minimize the total branch length at each stage of 
clustering of neighbors, starting with a star-like tree. Terminal gaps in the sequences 
may pose a problem in the distance matrix estimation, but no signs of bias have also 
been reported (Kuhner and Felsenstein 1994). The main difference between these 
methods is the assumption of a molecular clock in the UPGMA. Distance methods 
are computationally very fast and suitable for large data sets. Some loss of 
evolutionary information data may occur when considering pairwise distances (Steel 
et al. 1988; Whelan et al. 2001). This is not, however, believed to compromise the 
accuracy of phylogeny estimation (Felsenstein 2004). The NJ method sometimes 
estimates negative branch lengths that are difficult to interpret (Kuhner and 
Felsenstein 1994).  
Several models of nucleotide or amino acid substitution can be used for phylogenetic 
inference. Among the widely used models are Jukes-Cantor, the Kimura two 
parameter (K2P), Felsenstein 1981, Hasekawa, Kishino, and Yano (HKY85), General 
reversible and LogDet (Felsenstein 2005). Jukes-Cantor is a basic model assuming 
equal base frequencies and all substitutions at equal rates. The K2P model assumes 
equal nucleotide frequencies allowing, however, different rates for transitions and 
transversions. Felsenstein 1981 allows arbitrary base frequencies but equal rates for 
transitions and transversions. HKY85 allows unequal base frequencies and also 
provides a control for the  transition/tranversion (ts/tv) ratio. General reversible allows 
both arbitrary base frequencies and substitution rates. The LogDet distance measure 
was developed to deal with sequences that differ significantly in nucleotide 
composition (Barry 1987). Besides these models, several others exist, and the choice 
of model depends on the sequence data set. In addition to the choice of the model, 
computer software includes various user-defined parameters, such as ts/tv ratio, 
heterogeneity in the rate of evolution, and proportion of invariant sites (Kuhner and 
Felsenstein 1994), that can affect the results of the analysis.  
Further analysis to support the phylogenetic inference can be performed. 
Bootstrapping analysis is a resampling technique used to measure sampling error 
(Felsenstein 1985). It gives an idea about the reliability of branches and clusters. 
Quartet puzzling also allows investigation of the support of internal branching 
(Strimmer 1996). Likelihood mapping provides a means of visualizing phylogenetic 
content of the data set (Strimmer and von Haeseler 1997). It, like quartet puzzling, is 
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based on an analysis of the maximum likelihoods of the three fully resolved tree 
topologies computable for four sequences.  It can be used to define whether the 
phylogeny of the data set is tree-, net-, or star-like. 
2.3.3 MOLECULAR EPIDEMIOLOGY OF POLIOVIRUSES 
Enterovirus research has long been focused on polioviruses (PVs). Molecular 
epidemiological methods have been widely used in the global Poliomyelitis 
Eradication Initiative (World Health Assembly 1988). Molecular epidemiology has 
provided a means to establish typical geographic distribution of distinct genetic 
lineages of PV (Rico-Hesse et al. 1987; Lipskaya et al. 1995; Mulders et al. 1995a). 
Furthermore, it has helped to identify genetic sources of outbreaks and sporadic 
cases of poliomyelitis (Pöyry et al. 1990; Kinnunen et al. 1991; Kew 1995; Mulders 
et al. 1995b; Mulders et al. 1997; Kew et al. 2002). The genotype demarcation for 
PV was determined as a 15% divergence in the 150-nt VP1/2A junction region of 
the genome (Rico-Hesse et al. 1987).  This region was the traditional target for 
studies in PV, until the entire VP1 was shown to be the most reliable target for 
molecular epidemiological studies (reviewed in Kew et al. 2005). 
2.3.4 MOLECULAR EPIDEMIOLOGY OF NON-POLIO ENTEROVIRUSES 
Recently, genetic relationships of other emerging enteroviruses have been under 
extensive investigation. Molecular epidemiology of several HEV-B viruses, such as 
CV-A9 (Santti et al. 2000), CV-B4 (Mulders et al. 2000), CV-B5 (Kopecka et al. 
1995), E-11 (Lukashev et al. 2002; Oberste et al. 2003a; Chevaliez et al. 2004), E-13 
(Avellon et al. 2003; Mullins et al. 2004), and E-19 (Lukashev et al. 2003b), has 
been studied. The molecular epidemiology of other species of HEV, including CV-
A24 (Dussart et al. 2005) and EV-71 (Brown et al. 1999), has also been examined. 
As a result of the studies, trends in the enterovirus genetics have been revealed. 
Enterovirus species are claimed to exist as a worldwide pool of genetic material that 
is constantly evolving (Lukashev et al. 2003a). 
2.3.4.1 MOLECULAR TYPING OF ENTEROVIRUSES 
The capsid protein coding region is the most variable in the picornavirus genome 
(Palmenberg 1989). The sequence of the capsid protein VP1 has been shown to 
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correlate well with the serotype of enteroviruses (Oberste et al. 1999b; Oberste et al. 
1999c). Different approaches have been used to genetically define the “serotype” of 
an unknown enterovirus using either the entire VP1-coding gene (Oberste et al. 
2000; Oberste et al. 2003b) or part of it (Caro et al. 2001; Norder et al. 2001; 
Palacios et al. 2002b; Thoelen et al. 2003). Criteria for sequence homology have 
been defined (Oberste et al. 2000). VP1 nucleotide sequence identity of more than 
75% to a certain reference strain in GenBank indicates that the unknown sample is 
of homologous serotype, provided that the second-highest identity is less than 70%. 
Furthermore, the VP1 sequences of the same serotype have been demonstrated to 
form a homologous cluster in a phylogenetic tree (Oberste et al. 1999c; Caro et al. 
2001; Norder et al. 2001). Since molecular typing has become widely used for the 
characterization of unknown enterovirus strains, new types have been assigned 
based on the sequence of the VP1 capsid protein coding gene. Recently, however, 
evidence has emerged that enteroviruses within a species may evolve as a genetic 
continuum, which obscures the 75% percentage nucleotide identity demarcation 
assigned for serotypes (Brown et al. 2005). 
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3 AIMS OF THE STUDY 
GENERAL CONTEXT 
Molecular tools (i.e. partial genome sequencing) have been widely used to elucidate 
the epidemiology of many important viruses such as polioviruses. Monitoring the 
progress of the global Poliomyelitis Eradication Initiative (Kew 1995; Mulders et al. 
1997; Kew et al. 2005) has revealed interesting features of the genetic diversity of 
polioviruses and has brought along increasing interest towards non-polio 
enteroviruses. A series of studies on the molecular epidemiology of non-polio 
enteroviruses was started at the Enterovirus laboratory of the National Public Health 
Institute, Helsinki, Finland, to determine whether the evolutionary pattern of other 
HEVs including CV-B4 (Mulders et al. 2000) and CV-B5 (M. Mulders, pers. 
comm.), was similar to polioviruses. During the last decade E-30 has frequently 
been isolated in cases of aseptic meningitis in Europe. It was the increased epidemic 
activity of E-30 that prompted us to study its molecular epidemiology.  
Another “activity” relevant to the current study was the efforts of the Finnish Otitis 
Media Cohort Study (FinOM Cohort) to characterize the role of specific pathogens 
in acute otitis media (AOM). The FinOM Cohort Study, carried out in Tampere, 
Finland, in 1994-1997, revealed that HRVs were frequently found in AOM cases in 
young children (Vesa et al. 2001). We therefore broadened our scope to include 
HRVs. At that time, little knowledge existed about the genetic relationships of 
HRVs and no molecular tools were yet available for HRVs. We had access to the 
FinOM Cohort field isolates of HRVs and developed molecular tools for their 
characterization. While processing them, it became clear that the genetic differences 
between different HRV strains were sufficiently large to enable “genetic typing” of 
HRVs. We therefore decided to perform systematic analysis of the partial genome 
sequences of all prototype strains of HRV. 
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Specific questions to which answers were sought:
1. What is the molecular epidemiological pattern of E-30 isolated in different 
parts of Europe? 
2. What are the genetic relationships of recent field isolates of HRV? 
3. Is it possible to identify the serotype of an HRV strain using partial genome 
sequencing in the capsid coding region? 
4. Are the relationships of the HRV prototype strains different in distinct 
genomic regions, specifically in the capsid coding region and the RNA-
dependent RNA polymerase coding region? 
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4 MATERIALS AND METHODS 
The laboratory methods used are standard laboratory practices that are described in 
detail in the original articles (I-IV). Only a brief overview is given here. 
4.1 VIRUS STRAINS 
The E-30 field isolates had originally been isolated in different parts of Europe and 
other regions. The origins of the strains are provided in Study I.  The prototype 
strain Bastianni was purchased from the American Type Culture Collection (ATCC; 
Manassas, VA, USA). Propagation of the strains and confirmation of serotypes are 
described in Study 1. 
The HRV clinical samples (II-IV) isolated in the FinOM Cohort study, are described 
in detail in (Blomqvist et al. 1999) and are also listed in Table 4. The HRV prototype 
strains (III, IV) are listed in Table 5. The strains were either purchased from ATCC or 
received as a gift from the Haartman Institute, University of Helsinki, Finland; Janssen 
Pharmaceuticals, Beerse, Belgium; or the National Institute for Public Health and the 
Environment, Bilthoven, The Netherlands. HRV31 was also received from D. Blaas, 
University of Vienna, Austria. The HRV strain Hanks was provided courtesy of F. 
Hayden, University of Virginia, Charlottesville, VA, USA.  The passaging of 
rhinoviruses is described in Studies II-IV. 
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Table 4. Human rhinovirus clinical isolates used in Studies II-IV. 
Code Sample type Sample date  Code Sample type Sample date 
       
6253sep94 NPA 140994  8022nov95 NPA 171195 
6653oct94 NPA 031094  7137dec95 MEF 051295 
7430oct94 NPA 281094  7425dec95 NPA 131295 
7506mar95 NPA 240395  7052dec95 MEF 141295 
9257apr95 NPA 050495  7113dec95 NPA 221295 
5700may95 NPA 090595  6895jan96 NPA 270196 
7931may95 NPA 230595  8570feb96 MEF 260296 
5928may95 NPA 310595  8571feb96 NPA 260296 
6562may95 NPA 310595  7922mar96 NPA 010396 
6353jun95 NPA 080695  9316mar96 MEF 180396 
7062jun95 NPA 160695  9317mar96 MEF 180396 
9129jun95 NPA 210695  9318mar96 NPA 180396 
8057jun95 NPA 290695  7181may96 NPA 020596 
9702jul95 NPA 130795  6155may96 NPA 060596 
6682jul95 NPA 170795  7389may96 NPA 220596 
6322jul95 NPA 190795  7031may96 NPA 290596 
8452jul95 NPA 210795  7746aug96 NPA 050896 
7576aug95 NPA 220895  8643aug96 NPA 050896 
8925sep95 NPA 050995  7910aug96 NPA 070896 
6506sep95 NPA 080995  8169aug96 NPA 200896 
7774sep95 NPA 120995  8317aug96 NPA 280896 
6684sep95 NPA 200995  8507aug96 NPA 280896 
6939sep95 NPA 240995  9863sep96 MEF 030996 
6540sep95 MEF 250995  9864sep96 NPA 030996 
9166sep95 NPA 270995  7850sep96 NPA 110996 
6735oct95 NPA 041095  7790sep96 NPA 170996 
7821oct95 MEF 171095  7851sep96 MEF 170996 
7678nov95 NPA 011195  7852sep96 NPA 170996 
7160nov95 NPA 041195  8358oct96 NPA 071096 
7781nov95 NPA 151195  9056oct96 NPA 211096 
8001nov95 NPA 151195        
39
Table 5. Human rhinovirus prototype strains used in Studies III and IV. 
* RIVM, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; HI, 
Haartman Institute, University of Helsinki, Finland; ATCC, American Type Culture Collection, 
Manassas, VA, USA; Janssen, Janssen Pharmaceuticals, Beerse, Belgium; Vienna, D. Blaas, University
of Vienna, Austria; Charlottesville,  F. Hayden, University of Virginia, Charlottesville, VA, USA.  
Serotype Prototype strain Origin* Serotype Prototype strain Origin* 
            
1A Echo 28 RIVM 51 F01-4081 RIVM 
1B B632 RIVM 52 F01-3772 RIVM 
2 HGP HI 53 F01-3928 RIVM 
3 FEB RIVM 54 F01-3774 RIVM 
4 16/60 RIVM 55 WIS 315E RIVM 
5 Norman RIVM 56 CH82 RIVM 
6 Thompson RIVM 57 CH47 Janssen 
7 68-CV 11 RIVM 58 21-CV 20 RIVM 
8 MRH-CV 12 RIVM 59 611-CV 35 RIVM 
9 211-CV 13 RIVM 60 2268-CV 37 RIVM 
10 204 CV 14 RIVM 61 6669-CV 39 RIVM 
11 1-CV 15 RIVM 62 1963M-CV 40 RIVM 
12 181 CV 6 RIVM 63 6360-CV 41 RIVM 
13 353 RIVM 64 6258-CV 44 RIVM 
14 1059 RIVM 65 425-CV 47 RIVM 
15 1734 RIVM 66 1983-CV 48 RIVM 
16 11757 ATCC 67 1857-CV 51 RIVM 
17 33342 RIVM 68 F02-2317-Wood RIVM 
18 5986-CV 17 RIVM 69 F02-2513-Mitchinson RIVM 
19 6072-CV 18 RIVM 70 F02-2547-Treganza RIVM 
20 15-CV 19 ATCC 71 SF365 RIVM 
21 47-CV 21 RIVM 72 K2207 RIVM 
22 127-CV 22 RIVM 73 107E RIVM 
23 5124-CV 24 RIVM 74 328A RIVM 
24 5146-CV 25 RIVM 75 328F RIVM 
25 5426-CV 12 RIVM 76 H00062 RIVM 
26 5660-CV 27 RIVM 77 130-63 RIVM 
27 5870 CV 28 RIVM 78 2030-65 RIVM 
28 6101-CV 29 RIVM 79 101-1 RIVM 
29 5582-CV 30 RIVM 80 277G Janssen 
30 106F RIVM 81 483F2 Janssen 
31 140F RIVM, Vienna 82 3647 Janssen 
32 363 RIVM 83 Baylor 7 Janssen 
33 1200 RIVM 84 432D Janssen 
34 137-3 RIVM 85 50-525-CV-54 Janssen 
35 164A ATCC 86 121564-Johnson Janssen 
36 342H RIVM 87 F02-3607-Corn ATCC 
37 151-1 RIVM 88 
CVD-01-0165-
Dambrauskas Janssen 
38 CH79 HI 89 41467-Gallo Janssen 
39 209 RIVM 90 K2305 Janssen 
40 1794 RIVM 91 JM1 Janssen 
41 56110 RIVM 92 SF-1662 Janssen 
42 56822 RIVM 93 SF-1492 Janssen 
43 58750 ATCC 94 SF-1803 Janssen 
44 71560 Janssen 95 SF-998 ATCC 
45 Baylor 1 RIVM 96 SF-1426 Janssen 
46 Baylor 2 RIVM 97 SF-1372 Janssen 
47 Baylor 3 RIVM 98 SF-4006 Janssen 
48 1505 RIVM 99 604 Janssen 
49 8213 RIVM 100 K6579 Janssen 
50 A2 No.58 RIVM unnumbered   Hanks Charlottesville 
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4.2 RHINOVIRUS ISOLATION IN CELL CULTURE AND RNA ISOLATION 
A rhinovirus-sensitive strain of the HeLa cell line provided by E. Arruda (University 
of Virginia, Charlottesville, VA, USA) was used for the isolation of rhinoviruses (II-
IV). Rhinovirus isolation procedure for rolling tubes at 33°C was applied (Couch 
1992). The RNA was isolated from 100 μl cell culture homogenate with a 
commercial RNA isolation kit (RNeasy Total RNA kit, Qiagen, GmbH, Hilden, 
Germany). RNA extracts were frozen and stored at -70°C until use.  
4.3 RT-PCR AND DETECTION OF AMPLICONS 
The procedure for RT-PCR has been described in Mulders et al. (2000). The cDNA 
synthesis was carried out for 1 h in a reaction volume of 10 μl, which contained 1 μl 
of heat-denatured RNA, 25 mM Tris–HCl (pH 8.3 at 25°C), 5 mM MgCl2, 50 mM 
KCl, 2 mM DTT, 1 mM dNTPs (Boehringer Mannheim), 2 U avian myeloblastosis 
virus reverse transcriptase (Finnzymes), 4 U RNase inhibitor (Promega), and 12.5 
pmol of primer. A mixture of mineral oil (Sigma) and DynaWax (Finnzymes) in 
ratio of 7:1 was applied as overlay. Upon completion of the RT reaction, the sample 
was heated at 95°C for 5 min and then chilled to 4°C. For PCR, the reaction volume 
was adjusted to 50 μl by adding 4 μl of 10x PCR buffer (0.1 M Tris–HCl, pH 8.8 at 
25°C, 0.5 M KCl, 1% Triton X-100), 0.75 μl of 50 mM MgCl2, 12.5 pmol of both 
primers, 1 U recombinant Thermus brockianus DNA polymerase (DyNAzyme II; 
Finnzymes), and distilled water. Cycling conditions were as follows: 1 min at 94°C, 
followed by 35 cycles of 1 min at 94°C, 1 min at 42°C, and 2 min 30 s at 72°C. The 
cDNA synthesis and PCR were performed as separate steps in Studies I-III. In Study 
IV, RT-PCR were carried out in a single-tube fashion (Oberste et al. 2000). The 
oligonucleotide primers used in all studies are provided in Table 6. The PCR 
products were visualized after electrophoresis in an ethidium bromide –stained 2% 
agarose gel. 
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4.4 SEQUENCING 
PCR products were purified prior to sequencing either directly using a PCR 
Purification kit (QIAquick, Qiagen) or excised from the gel and purified using the 
Gel Extraction kit (QIAquick, Qiagen). The purified products were stored at -20°C
or directly used in cycle sequencing (ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction kit; Applied Biosystems, Espoo, Finland). Automated 
sequencer ABI PRISM 377 was used for sequencing in Studies I-IV and ABI 
PRISM 310 in Study IV. 
4.5 SEQUENCE ANALYSIS 
Sequence data were analyzed with Sequencing Analysis (version 3.1; Applied 
Biosystems) and Sequence Navigator (version 1, Applied Biosystems). Multiple 
sequence alignments were performed with the PileUp (I) component of the GCG 
program (version 10, Genetics Computer Group, Inc., USA) and ClustalX version 
1.64b (II, III) or 1.83 (IV) (Thompson et al. 1997). Alignments were generated with 
default parameters and adjusted manually. Distance matrices were estimated using 
DNAdist and PROTdist from PHYLIP [Phylogeny Inference Package, version 
3.572c, (I-III); 3.6 (IV)] (Kuhner and Felsenstein 1994) using a ML method (I-III) 
and the K2P model (IV). The dendrograms were drawn with Neighbor (PHYLIP) 
using the UPGMA (I) and NJ (II-IV) options. The dendrograms were visualized 
with Njplot (Perriere 1996) or Treeview version 1.5.3 (Page 1996). Bootstrap 
analysis (Hillis 1993) was performed using Seqboot (PHYLIP) with 100 or 1000 
replicates. Quartet puzzling (I) was performed with PUZZLE (version 4.0) 
(Strimmer 1996) with 1000 replicates. The likelihood mapping analysis (II) was 
performed with PUZZLE (version 4.0) (Strimmer and von Haeseler 1997) with 1000 
random quartets and the HKY85 model of substitution (Hasegawa et al. 1985).  
Similarity analysis and Bootscanning (Salminen et al. 1995) were used to identify 
recombinant strains in the complete genome alignments. They were performed with 
SimPlot software package version 2.5 or 3.5.1 (Lole et al. 1999).  SimPlot calculates 
and plots the identity (%) of the query sequences to reference sequences in a sliding 
window. Nonrecombinant sequences show homology at a similar level throughout 
the genome, whereas for recombinants the highest homology sequence depends on 
the region. In bootscanning, a query sequence is aligned with reference sequences, 
phylogenetic trees are constructed, bootstrapping analysis is performed, and 
bootstrap values are plotted in segments. Nonrecombinant sequences show high 
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bootstrap values with one reference strain throughout the genome, while 
recombinants cluster with two or more parental strains. A sliding window of 200 
nucleotides moving in steps of 20 nucleotides was used for both analyses. For 
bootscanning, the NJ method and K2P model of substitution were used, and the ts/tv 
ratio was estimated from the data set. Positions containing gaps were excluded from 
analyses. 
44
5 RESULTS AND DISCUSSION 
5.1 MOLECULAR EPIDEMIOLOGY OF ECHOVIRUS 30 CLINICAL 
ISOLATES (I) 
E-30 was included in the series of studies on molecular epidemiology of HEV-B 
viruses because of its clinical significance. One of the neurologic complications of 
enteroviruses is aseptic meningitis. Echoviruses have been found to be responsible 
for 80-90% of all viral meningitis (Diedrich et al. 1995). During the 1990s E-30 was 
frequently isolated in cases of aseptic meningitis (Mori et al. 1995; Hovi et al. 1996; 
Maguire et al. 1999). E-30 strains isolated in distinct areas had been shown to vary 
genetically (Gjoen et al. 1995). To illustrate the molecular epidemiological pattern 
of European E-30 isolates, we sequenced three genomic regions of 129 E-30 field 
isolates. While we were processing these, the epidemic activity of E-30 continued to 
increase. Two other groups published a similar characterization focusing on 
different geographical areas and distinct genomic regions: in Scotland 5’NCR and 
VP4/VP2 were studied (Nairn and Clements 1999) and in USA the VP1 region 
(Oberste et al. 1999a). A study of 13 German strains on a partial VP1 region was 
also published (Kunkel and Schreier 2000). A specific diagnostic PCR for E-30 has 
subsequently been developed (Kilpatrick et al. 2001), and a report on E-30 isolations 
in USA has been published (Centers for Disease Control and Prevention 2003). A 
study summarizing 318 different E-30 strains worldwide was published in 2002 by 
Palacios et al. (2002a). Recently, persistent circulation (Chambon et al. 2001; Bernit 
et al. 2004) and sporadic outbreaks of E-30 have been described in various parts of 
the world (Manzara et al. 2002; Wang et al. 2002; Ozkaya et al. 2003; Vestergaard 
et al. 2004). A RFLP-based identification tool has also been developed to monitor 
cases of viral meningitis with regard to E-30 (Charrel et al. 2004). 
The genetic regions in our study of E-30 included a 420-nt stretch in the VP4/VP2 
coding region, the entire VP1 (876 nt), and a 150-nt VP1/2A region. All 130 E-30 
strains, including the prototype strain Bastianni, were sequenced in the VP4/VP2 
region, and based on the observed clustering, a subset of strains was sequenced in 
other regions. E-30 was found to differ from other analyzed enteroviruses in that the 
genetic variation of E-30 strains was markedly lower in all studied regions. 
However, the amino acid variation of E-30 in VP1 exceeded that found for CV-B4, 
although the nucleotide variation was lower.  
Several different co-circulating genetic lineages have been found for PVs (Rico-
Hesse et al. 1987; Mulders et al. 1995a), CV-A9 (Santti et al. 2000), CV-B4 
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(Mulders et al. 2000), CV-B5 (M. Mulders, pers. comm.), E-11 (Oberste et al. 
2003a), and CV-A24 (Dussart et al. 2005), while a single genotype of E-30 has 
prevailed in Europe for more than two decades (Study I). The prevailing strains 
differ significantly from the prototype Bastianni, as also shown by others (Oberste et 
al. 1999a; Kunkel and Schreier 2000). Furthermore, the previous genetic lineages 
were found to be replaced by the dominant lineage. This epidemiological pattern of 
E-30, where prevailing lineages displace less established ones, as described in Study 
I, resembles that of influenzaviruses A and B, a view shared by others (Palacios et 
al. 2002a). In influenzaviruses the prevailing lineages are selected on the basis of 
immune escape (Scholtissek 1996). In addition, the observation of relatively large 
amino acid variation in VP1 among the studied E-30 strains could indicate antigenic 
differences. This study did not include characterization of possible antigenic 
alterations. Later antigenic analyses of E-30 field strains have not revealed a pattern 
connected to genetic clustering, although differences exist (C. Savolainen-Kopra, 
unpublished data). Differences in ability to cause functional impairment and cell 
death in cultured human pancreatic β-cells have subsequently been demonstrated 
among E-30 strains of distinct molecular lineages (Roivainen et al. 2002). Certain 
strains of E-30, not clustering together, though, in Study I, were clearly more 
destructive than the E-30 prototype strain Bastianni. Recently, the mode of 
epidemiology found for E-30, successive replacement of prevailing clusters, has 
been suggested to describe the current situation with several enteroviruses, being, 
however, less clear-cut for some serotypes (Lukashev 2005). 
Besides European strains, our study included one strain from Japan, two strains from 
Russia, two strains from Byelorussia, and two strains from Israel. All of these 
clustered among the prevailing genotype. However, worldwide, evidence has 
emerged of more than one co-circulating genotype (Oberste et al. 1999a; Bailly et al. 
2002; Palacios et al. 2002a; Wang et al. 2002). Figure 3 illustrates the prevailing 
genotype also found widely outside Europe and the separate genotypes formed by 
recent isolates from the Philippines and Colombia. The existence of a predominant 
genetic type is said to correlate with the temporal dynamics of E-30 isolation 
(Oberste et al. 1999a). Recent reports have shown strains of E-30 frequently 
involved in recombination (Lukashev et al. 2003a; Oberste et al. 2004a). The 
nonstructural part of the E-30 Bastianni genome has spread through recombination 
to many other serotypes isolated in the late 1990s (Lukashev et al. 2003a).  While 
this is not likely to be a special characteristic of E-30 Bastianni, it does support the 
suggestion of Lindberg and coworkers (2003) that P2-P3 regions can be universally 
used among different HEV-B viruses. Several virtually disappeared genotypes of E-
30 may provide important gene transfer to newer strains of other serotypes of HEV.  
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Figure 3. Neighbor-joining dendrogram of the E-30 VP1 sequences (876 nt) (Study 
I) added with GenBank sequences published in other studies (in boldface). Numbers 
indicate Bootstrap values (1000 replicates); only values >70% are shown. 
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5.2 GENETIC RELATIONSHIPS OF CLINICAL ISOLATES OF HUMAN 
RHINOVIRUSES FROM SUCCESSIVE EPIDEMIC SEASONS (II) 
An opportunity opened up for us to study genetic diversity and molecular evolution 
of HRV field strains and compare these with the closely related HEV, as in the 
FinOM Cohort study, which focused on the role of different risk factors in AOM, 
833 rhinovirus-positive recently collected specimens were found (Blomqvist et al. 
2002a; Nokso-Koivisto et al. 2004). From these, a random selection of 61 samples 
was included in the analysis of genetic diversity. The sequencing was initiated from 
the genomic region coding for capsid proteins VP4/VP2. In enteroviruses, this 
region is known to be flanked by relatively conserved stretches, suitable for 
designing primers for strains of unknown sequence. Previous studies (Duechler et al. 
1987; Horsnell et al. 1995) have shown that HRVs can be divided into two major 
genetic clades. The larger of the clades is related to HRV1B and comprises the 
majority of the strains analyzed thus far. The smaller clade is related to HRV14. The 
genetic and evolutionary differences between these clades are marked, as can be 
seen in Figure 4.  Since these studies, very little new information on the genetic 
relationships of currently circulating strains has arisen. 
The reliability of phylogenetic information and the suitability of tree-like 
dendrograms for the alignment of rhinoviral sequences were tested with Likelihood 
mapping analysis (Strimmer and von Haeseler 1997). The results for both genetic 
clades indicate a well-resolved phylogeny and do not support a star-like evolution. 
Thus, we concluded that phylogenetic reconstruction in the form of a tree-like 
dendrogram was suitable for rhinoviruses. However, 10% of the test tree topologies 
in genetic group I of the Likelihood mapping analysis represent phylogenetic noise, 
possibly caused by a star-like evolution. In genetic group II, this value was 1.5%. 
This can also be seen in the longer terminal branches of the dendrogram of group I 
as compared with group II (Study II, Fig. 2). A possible intepretation of this might 
be that the strains in genetic group I have a longer time interval from the first 
diversions to this point. The tree of group II has branched more frequently during 
the same time interval.  
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Figure 4. Phylogenetic relationships of the completely sequenced HRV strains in the 
VP4/VP2 capsid coding region. Neighbor-joining dendrogram of 140 amino acids. 
Based on the clustering in the VP4/VP2 region, the sequences of the 61 analyzed 
rhinovirus strains were divided into the two formerly known clades. The HRV1B-
related group comprised 24 of the clinical isolates, while 37 isolates clustered in the 
HRV14-related group. The sequences formed temporal clusters covering one 
epidemic season. However, certain clusters had members isolated in successive 
seasons. In addition, co-circulation of separate genetic lineages was found. 
Furthermore, reappearance of a cluster after disappearing for a given season was 
seen. This might, however, be due to the limited number of strains studied. Several 
separate genetic lineages, possibly representing serotype-like clusters, could be 
observed among the studied rhinovirus field isolates. The range of evolutionary 
distances was very large, from identical sequences to more than 30% divergence. 
With an approximate evolutionary distance of 20% or more, certain field strains 
could be linked to a prototype strain, even though the analysis included only five 
completely sequenced prototype strains. An example of this is a pair formed by 
5700may95 and HRV16.  
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5.3 ALL BUT ONE HUMAN RHINOVIRUS PROTOTYPE STRAINS CLUSTER 
IN THE TWO KNOWN CLADES IN THE CAPSID REGION (III) 
As the genetic relationships of HRV field strains appeared complex (Study II), we 
performed a systematic analysis of all designated prototype strains of HRV in the 
same genetic region. A total of 97 HRV prototype strains were sequenced in the 
VP4/VP2 coding region. The previously sequenced five prototype strains were 
included in the analysis. The strains included two subtypes of HRV1 and an 
unnumbered suggested new serotype Hanks. Seventy-six strains clustered in the 
HRV1B-related group, designated HRV-A. Twenty-five strains clustered in the 
HRV14-related group, designated HRV-B. HRV87 did not cluster with either of the 
major clades, but was found to be close to EV-70. HRV87 has subsequently been 
further characterized and reclassified as a member of HEV-D (Blomqvist et al. 
2002b). The division of HRV prototype strains into two clusters is illustrated as a 
dendrogram in Figure 5. The evolutionary variation maxima within the two groups 
were 41% and 34% at the nucleotide level and 28% and 20% at the amino acid level, 
respectively. These differences are roughly the same as those found for 
enteroviruses in the capsid coding region. In the publication of Study III, the HRV31 
sequence included in the dendrogram was erroneous; HRV31 had been 
contaminated with HRV32 (Vlasak et al. 2003). The correct HRV31 was obtained 
from Vienna and the sequence revised in GenBank in June 2003 (AF343583). The 
revised sequence is included in Figure 5. Subclusters or distinct lineages of HRV 
can be seen, but the branching is not well supported by Bootstrapping. Furthermore, 
the model of nucleotide substitution used has some effect on tree topology, albeit the 
members of the sublineages stay coherent regardless of the method of evolutionary 
reconstruction.  
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Figure 5. a) Neighbor-joining dendrogram of HRV-A strains in the VP4/VP2 capsid 
coding region (420 nt). Numbers indicate Bootstrap values (1000 replicates); only 
values >70% are shown. The blue bar indicates an approximate demarcation of 20%. 
One cluster of field isolates from different epidemic seasons and the closest 
prototype strain highlighted. 
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Figure 5. b) Neighbor-joining dendrogram of HRV-B strains in the VP4/VP2 capsid 
coding region (420 nt). Numbers indicate Bootstrap values (1000 replicates); only 
values >70% are shown. The blue bar indicates an approximate demarcation of 20%. 
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Judging from the phylogenetic tree in the VP4/VP2 region, the field isolates might 
represent as many as 19 different serotypes (Fig. 5a and b). However, as noted 
before for enteroviruses (Oberste et al. 1998; Oberste et al. 1999b; Oberste et al. 
1999c; Mulders et al. 2000), the capsid coding region outside VP1 may not always 
be conclusive in defining the serotype. Furthermore, determining the closest 
prototype strain to field strains is difficult because five pairs of prototype strains 
(HRV25/62, HRV29/44, HRV8/95, HRV1A/1B, HRV21/Hanks) have an 
evolutionary distance of less than 10%. The VP1 sequences of all HRV prototype 
strains have since been published (Ledford et al. 2004; Laine et al. 2005). The 
overall pattern with the major clades and clusters was identical to the one seen in 
VP4/VP2. The same prototype strains were found to be close to each other also in 
the VP1 coding part of the genome. We therefore suggest that in the genetic typing 
of HRV the term “the closest related prototype strain” be used instead of aiming at a 
definite serotype. HRV do not show a coherent distance pattern throughout all 
serotypes in the capsid region, but exist as a genetic continuum within the major 
clades HRV-A and HRV-B. This is similar to the variation of viruses within HEV-C 
(Brown et al. 2005). Other groups have subsequently published sequence data on 
rhinoviruses isolated from respiratory samples in GenBank (Arden et al. 2004; 
Diedrich et al. 2004). These data suggest results similar to those of Studies II and 
III; sequences of field isolates cluster close to a prototype strain, but the divergence 
from the second closest prototype strain is not much larger. 
Strong genetic support for antigenic cross-reactivity emerges, as all pairs reported to 
have reciprocal cross-reactions (Cooney et al. 1973; Cooney et al. 1982) cluster 
together in VP4/VP2. In the figures of Study III, HRV12 and HRV78 did not cluster 
as close as in the dendrogram based on the K2P model (Fig. 5). Several pairs of one-
way cross-reactions (Cooney and Kenny 1970; Calhoun et al. 1974; Cooney et al. 
1982) also cluster close to each other, but some exist in different branches; however, 
always in the same major clade. Antigenic cross-reactions have not been studied for 
HRV8 and HRV95. They have only four divergent nucleotides and no amino acid 
changes in the 420-nt stretch in VP4/VP2. VP4/VP2 region, however, contains no 
amino acids of the known antigenic sites of rhinoviruses (Sherry and Rueckert 1985; 
Sherry et al. 1986; Skern et al. 1987; Verdaguer et al. 2000). Genetic closeness of 
HRV8 and HRV95 has subsequently been seen in VP1 (Ledford et al. 2004; Laine et 
al. 2005), and they have been suggested to be classified in a single serotype similar 
to HRV21 and HRVHanks (Ledford et al. 2004).   
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This study was the first systematic investigation of the capsid sequences of HRV 
prototype strains. It has been used as a basis for classification of rhinoviruses by the 
Picornavirus Study Group of the International Committee for the Taxonomy of 
Viruses (Stanway et al. 2005). Furthermore, the finding of the outlier nature of 
HRV87 originally made here and further studied by Blomqvist et al. (2002) and 
others (Ishiko et al. 2002; Ledford et al. 2004; Oberste et al. 2004b) has led to the 
classification of HRV87 as a member of HEV-D. These studies have prompted 
further discussions on the separation of entero- and rhinoviruses based on acid 
sensitivity. The titer of enterovirus 68, another strain of the same serotype as 
HRV87, was reduced by incubation at pH 3.0 (Blomqvist et al. 2002b; Oberste et al. 
2004b), although enteroviruses are generally considered acid-stable. Furthermore, 
all serotypes and strains of rhinoviruses may not be acid-labile (S. Blomqvist, pers. 
comm.). These issues have led to discussions and an official proposal by the 
Picornavirus Study Group that the enterovirus and rhinovirus genera should be 
combined to form a single genus (T. Hovi, pers. comm.).  
5.4  GENETIC CLUSTERING OF RHINOVIRUSES IN THE 
NONSTRUCTURAL PART OF THE GENOME SUPPORTS DIFFERENCES 
IN THE PHYLOGENETIC HISTORY OF STRAINS (IV) 
To enlarge the general picture of genetic relationships of HRV strains, we sequenced 
48 HRV prototype strains and 12 field strains in the partial RNA-dependent RNA 
polymerase (3D) coding part of the genome. The length of the analyzed part of the 
3D was 468 nt. A similar distribution to the major clades was seen as in the capsid 
part of the genome. All field strains clustered close to the same prototype strains as 
in the capsid region. Some differences in tree topology could be seen in HRV-A as 
compared with the VP4/VP2 tree. However, our analysis included only a subset of 
HRV serotypes, and it is possible that the sequences of the remaining prototype 
strains would affect the alignment.  
The location of one cluster of strains in the HRV-A dendrogram differed strikingly 
from the clustering seen in the VP4/VP2 region. This group comprised HRV8, 
HRV95, HRV45, and 6155may96. In 3D they were clearly separated from the rest of 
the HRV-A strains and designated as HRV-A’. Figure 6 displays the genetic 
relationships of 43 HRV-A prototype and field strains, including HRV-A’. HRV-A’ 
also formed a subcluster in the VP4/VP2, but nevertheless clustered within HRV-A. In 
VP1 and 2A, this group has been shown to form a cluster clearly distinct from HRV-A 
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(Laine et al. 2005). HRV-A’ may represent a group with a phylogenetic history that is 
different from that of other HRV and HEV. Different genomic regions of HRV-A’ 
may have evolved at different rates. The variation in the 3D part of the genome in 
HRV was generally larger than that seen in the correspondent part of HEV. 
Furthermore, HRV-B clustered closer to HEV than to HRV-A, unlike in the 
VP4/VP2 region. This is in accordance with the findings of Stanway et al. (1984) 
regarding HRV14.    
5.5 EVIDENCE FOR RECOMBINATION WITHIN HUMAN RHINOVIRUS 
GENOMES
The incongruence in the tree topology between the capsid region and the 
nonstructural region led us to suspect possible recombination events within HRV-A. 
This discrepancy is illustrated in a combined analysis of two distant segments of 
HRV prototype strains, the complete genome sequence of which has been published 
(Fig. 7). Furthermore, the long terminal branches, seen in the dendrograms of  HRV-
A have been considered as possible evidence of recombination (Schierup and Hein 
2000). Other reasons for long terminal branches might be heterogeneity in the rate of 
sequence evolution or bias in the ts/tv ratio. However, both of these have been 
observed to have an effect smaller than recombination (Schierup and Hein 2000). 
The default ts/tv ratio of 2 was used in the analyses. In Study II, the ratios were 
determined from the data sets. The ratios for other genomic regions have also been 
determined from the data sets (data not shown), and the default value of 2 was found 
to be applicable. In addition to long terminal branches, recombination can lead to 
more star-shaped genealogy (Schierup and Hein 2000). Some evidence of this was 
seen in Study II in the Likelihood mapping analysis of genetic group I (HRV-A), 
although the results still indicated a tree-like phylogeny. As variation among 
different HRV strains is large and different regions in the HRV genome might 
evolve at different rates, recombination may be difficult to prove based on partial 
genome sequences. As stated for HEV-B (Oberste et al. 2004a), evidence of 
recombination may be obscured by accumulation of nucleotide sustitutions.  
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Figure 6. Neighbor-joining dendrogram depicting phylogenetic relationships of 
HRV-A in the RNA-dependent RNA polymerase (3D) coding region (468 nt). 
Numbers indicate Bootstrap values (1000 replicates); only values >70% are shown. 
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Figure 7. Combined phylogenetic analysis of HRV prototype strains, the complete 
genome sequence of which has been published in the VP4/VP2 capsid coding region 
(left side) and in the RNA-dependent RNA polymerase (3D) coding region (right side). 
To elucidate the recombination hypothesis, all available HRV-A complete genome 
sequences (HRV1B D00239, HRV2 X02316, HRV9 (Leckie 1987), HRV16 
L24917, HRV39 AY751783, HRV85 (Stanway 1989), and HRV89 NC_001617) 
were plotted against each other in the SimPlot and Bootscan analyses. The results of 
these analyses for HRV2 are displayed in Figure 8. Most of the studied HRV-A 
genomes showed background similarity to each other, rarely exceeding 80%, except 
in the 5’NCR (data not shown). However, HRV2 and HRV39 were more closely 
related in the nonstructural part of the genome in Similarity plotting. High support 
for recombination between HRV2 and HRV39 was seen in Bootscanning analysis. 
The recombination breakpoint was localized in 2A (around nt 3220). However, due 
to the large genetic variation among all HRV-A strains, the exact location could not 
be pinpointed. Moreover, it is impossible to determine whether HRV39 is the real 
parental strain or is it perhaps another strain of HRV, the complete genome of which 
is unavailable. A recombination event may have happened early in the evolution of 
????
?????
????
?????
?????
?????
?????
????
?????
?????
?????
????
?????
????
?????
????
??????? ??
57
HRV2 and HRV39, but several subsequent point mutations have blurred the 
relationship to the parental strains. Interestingly, HRV2 belongs to the minor 
receptor group of HRV, whereas HRV39 is a member of the major receptor group. 
This could mean that the two viruses have simultaneously infected the same human 
cell with different receptors. The isolation years for prototype strains HRV2 and 
HRV39 are 1957 and 1962, respectively (Taylor-Robinson and Tyrrell 1962; 
Mufson et al. 1965), which does not rule out the possibility that they were  
circulating at the same time. However, as theoretically shown in the recombination 
evidence for HEV-B, two strains being related by recombination does not 
necessarily mean these serotypes were simultaneously present in the same host cell; 
the observed recombination may be due to serial recombination events (Oberste et 
al. 2004a). The same can be true for HRV-A 
Recombination has been shown to be frequent among different HEVs (Santti et al. 
1999; Andersson et al. 2002; Oprisan et al. 2002; Lindberg et al. 2003; Lukashev et 
al. 2003a; Lukashev et al. 2004). Similar to HEV, several HRV strains circulate 
simultaneously (Study II), and due to the large number of serotypes, it is likely that 
double infections occur. Why recombination was not observed among the field 
strains in our study may be because of the small number of strains sequenced in the 
3D region. Another reason why recombination is not seen more often in HRV might 
be the short duration of infection. Recombination has been considered to increase 
fitness of PV. The HRV recombinant progeny may be less fit to enrich in the virus 
population. However, only a small subset of HRV has thus far been completely 
sequenced. Information on complete genome sequences of HRV is needed to shed 
light on recombination events. Furthermore, it has been said for enteroviruses that 
knowing the serotype of an enterovirus isolate only means that one-third of its 
genome is more than 70% similar to the prototype strain isolated in the 1950s 
(Lukashev 2005). This has been considered the reason why it is so difficult to 
correlate an enterovirus serotype with the clinical manifestation. Recombination or 
gene transfer in the nonstructural part of the genome may also have important 
consequences in the pathogenicity of HRVs. 
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Figure 8. Complete genome sequence of Human rhinovirus (HRV) -2 plotted against 
other available complete genome HRV sequences. Upper panel: Similarity plotting 
analysis; lower panel: Bootscan analysis with Neighbor-joining method. A sliding 
window of 200 nt and steps of 20 nt were used for both analyses. 
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6 CONCLUSIONS 
As part of a series of studies elucidating molecular epidemiological relationships of 
HEV-B viruses, a prevalent enterovirus, echovirus 30 (E-30), was analyzed by 
partial genome sequencing of a total of 129 European field isolates. Compared with 
many other enteroviruses, including poliovirus, an atypical pattern was seen, with 
the prevailing genetic lineage replacing the previous lineages. 
A large collection of HRV-containing respiratory samples was available from 
another study, the FinOM Cohort Study, which aimed at characterizing the role of 
specific pathogens in AOM. To determine molecular epidemiological relationships 
of the close relatives of HEV, 61 HRV field strains were examined by sequencing of 
the VP4/VP2 capsid protein coding region. Currently circulating HRV field isolates 
were shown to cluster in the two established major genetic clades in the VP4/VP2 
genomic region. More than 60% of the strains clustered in the HRV14-related clade. 
Several co-circulating strains were observed, possibly representing different 
serotypes of HRV. 
To investigate the possibility of genetic typing of HRV, we analyzed all known 102 
HRV prototype strains in the genetic region coding for VP4/VP2. The first 
systematic genetic characterization of all designated HRV prototype strains was 
performed. All prototype strains, except HRV87, were shown to cluster in the two 
major clades, designated Human rhinovirus A (HRV-A) and Human rhinovirus B
(HRV-B).  The clades comprised 76 and 25 prototype strains, respectively. The field 
isolates could be linked to a prototype strain, enabling genetic typing of HRVs with 
the criterion “the closest prototype strain”. 
A total of 50 HRV prototype and 12 field strains were genetically analyzed in the 
RNA-dependent RNA polymerase coding region (3D). The same major clades were 
seen as in the capsid region. The variation of HRV in the 3D region was larger than 
that observed in the VP4/VP2 capsid coding region. This observation is in contrast 
to HEV, for which the variation in the capsid region exceeds that of the 3D region. 
Furthermore, the variation of HRV was found to exceed that of HEV in the 3D 
region. The general phylogenetic tree topology differed from that for the capsid 
coding region among HRV-A strains, suggesting possible recombination events.  
Evidence for recombination was obtained with Similarity and Bootscanning 
analyses of previously published complete genome sequences. Putative 
recombination was detected among the genomes of HRV2 and HRV39.  
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In this work, we have used phylogenetic methods to elucidate the genetic 
relationships of a group of viruses with large variation that hampers the development 
of medicines and vaccines. We have shown the genetic distribution of both the 
prototype strains of HRV and a collection of recently isolated field strains. Our 
results together with subsequently published VP1 data for HRV provide a taxonomic 
classification of all designated HRV prototype strains.  
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